Patents by Inventor Brian E. Fink

Brian E. Fink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOFURAN COMPOUNDS AS STING AGONISTS
    Publication number: 20240109899
    Abstract: The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: BRIAN E. FINK, EMILY CHARLOTTE CHERNEY, LIPING ZHANG, JULIAN C. LO, GRETCHEN M. SCHROEDER, TRAM N. HUYNH, DONNA D. WEI, VIJAY T. AHUJA, CLAUDE A. QUESNELLE
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11945834
    Abstract: The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: April 2, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brian E. Fink, Zheming Ruan
  • AGONISTS OF ROR GAMMAt
    Publication number: 20230295087
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 8, 2020
    Publication date: September 21, 2023
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
  • AGONISTS OF ROR GAMMAt
    Publication number: 20230242478
    Abstract: The present invention is directed to compounds of the formula [INSERT CHEMICAL STRUCTURE HERE}] wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 3, 2023
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Brian E. Fink
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11660311
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 30, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • AGONISTS OF ROR GAMMAt
    Publication number: 20220306630
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 29, 2022
    Inventors: Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11427610
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Libing Chen, Audris Huang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11339185
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20220117995
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 21, 2022
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20210253624
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 19, 2021
    Inventors: Brian E. FINK, Yufen Zhao, Libing Chen, Audris Huang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10953032
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dharmpal S. Dodd, Brian E. Fink, Yong Zhang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10947263
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 16, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lan-Ying Qin, Zheming Ruan, Libing Chen, Scott Hunter Watterson, Brian E. Fink
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20210002323
    Abstract: The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 7, 2021
    Inventors: Brian E. FINK, Zheming Ruan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10744150
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 18, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Lan-ying Qin, Zheming Ruan, Yufen Zhao, Lalgudi S. Harikrishnan, Muthoni G. Kamau, Steven J. Walker
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200253997
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 13, 2020
    Inventors: Dharmpal S. Dodd, Brian E. Fink, Yong Zhang
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200223883
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 30, 2018
    Publication date: July 16, 2020
    Inventors: Lan-Ying Qin, Zheming Ruan, Libing Chen, Scott Hunter Watterson, Brian E. Fink
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200079815
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G, Kamau, Lalgudi S. Harikrishnan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10519187
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 31, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • TGF beta receptor antagonists
    Patent number: 10399987
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myer Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Robert M. Borzilleri, Gopikishan Tonukunuru, Jayakumar Sankara Warrier
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190248828
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan